Vanguard Global Advisers
TMCI icon

Vanguard Global Advisers’s Treace Medical Concepts TMCI Stock Holding History

Vanguard Global Advisers’s Portfolio TMCI Stock Details TMCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64.7K Hold
16,247
– – ﹤0.01% 2973
2026
Q1 		$21.8K Buy
+16,247
New +$32.4K ﹤0.01% 3285

Other funds holding TMCI

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GA
Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
CBU
CIBC Bancorp USA Chicago, Illinois $82.3B AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
WCM
Weber Capital Management San Francisco, California $118M AUM

Vanguard Global Advisers's TMCI Position: Q2 2026 in Review

Vanguard Global Advisers held its Treace Medical Concepts (TMCI) position steady in Q2 2026 at 16,247 shares worth $64.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2973.

Vanguard Global Advisers first reported a position in TMCI in Q1 2026 and has held it in 2 quarters since. 107 funds tracked by Wall St. Rank hold TMCI as of Q2 2026.

  • Vanguard Global Advisers held 16,247 shares of Treace Medical Concepts worth $64.7K as of Q2 2026.
  • Vanguard Global Advisers left its Treace Medical Concepts share count unchanged in Q2 2026.
  • Treace Medical Concepts made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2973 holding.
  • Vanguard Global Advisers first reported a position in Treace Medical Concepts in Q1 2026 and has held it in 2 quarters since.
  • 107 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.